Key Takeaway: Precision BioSciences has reported its third quarter 2023 financial results, showcasing advancements in its gene editing pipeline. The company is set to present late breaker data for PBGENE-HBV at The Liver Meeting in November 2023. Additionally, they have expanded their portfolio with PBGENE-PMM, aimed at treating m.3243 associated primary mitochondrial disease.
Price reaction · baseline $11.997 (2023-11-06 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-2.5%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of late breaker data at The Liver Meeting shows progress.
Focus on in vivo gene editing pipeline indicates strong R&D commitment.
Expansion of portfolio with PBGENE-PMM highlights innovation.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 – Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline – Expanded portfolio with PBGENE-PMM as a potentially curative treatment for m.3243 associated primary mitochondrial
Frequently Asked Questions
What financial results did Precision BioSciences report?
Precision BioSciences reported its third quarter 2023 financial results, highlighting advancements in its gene editing pipeline.
When will Precision present PBGENE-HBV data?
Precision will present late breaker PBGENE-HBV data at The Liver Meeting in November 2023.
What is PBGENE-PMM?
PBGENE-PMM is a potentially curative treatment for m.3243 associated primary mitochondrial disease.
What focus did Precision highlight during the R&D Day?
Precision highlighted its exclusive focus on its in vivo gene editing pipeline during the R&D Day.